Collaboration Agreements

1,992 Contracts & Agreements

Collaboration agreements include contracts that define joint initiatives between a company and other parties.

Browse Collaboration Agreements by Industry

Aerospace & Defense (1 contract from 1 company)
Air Freight & Logistics (2 | 1)
Auto Components (3 | 2)
Automobiles (1 | 1)
Biotechnology (1,215 | 301)
Chemicals (8 | 3)
Communications Equipment (2 | 1)
Construction & Engineering (1 | 1)
Consumer Finance (5 | 2)
Diversified Consumer Services (4 | 3)
Electrical Equipment (21 | 5)
Electronic Equipment, Instruments & Components (5 | 1)
Energy Equipment & Services (4 | 3)
Entertainment (3 | 2)
ETFs (9 | 2)
Food Products (1 | 1)
Health Care Equipment & Supplies (112 | 42)
Health Care Providers & Services (8 | 7)
Health Care Technology (4 | 3)
Hotels, Restaurants & Leisure (1 | 1)
Household Durables (3 | 1)
Household Products (1 | 1)
Independent Power & Renewable Electricity Producers (1 | 1)
Interactive Media & Services (1 | 1)
Internet & Direct Marketing Retail (1 | 1)
Life Sciences Tools & Services (26 | 13)
Machinery (1 | 1)
Media (1 | 1)
Metals & Mining (6 | 3)
Oil, Gas & Consumable Fuels (5 | 3)
Personal Products (2 | 1)
Pharmaceuticals (236 | 117)
Semiconductors & Semiconductor Equipment (9 | 6)
Software (4 | 4)
SPACs, Investment, & Acquisition Companies (11 | 5)
Specialty Retail (1 | 1)
Unassigned Industry (273 | 124)

Recent Contracts

Amended and Restated Research and Collaboration Agreement, dated August 9, 2024, by and between Aarvik Therapeutics, Inc. and the Registrant (ArriVent Biopharma, Inc., Filed With SEC on November 14, 2024)
Fourth Amendment to Collaboration, License and Option Agreement, dated September 16, 2024, by and between Curis, Inc. and Aurigene Discovery Technologies Limite (CURIS INC, Filed With SEC on November 14, 2024)
Third Amendment to Collaboration, License and Option Agreement, dated June 4, 2020, by and between Curis, Inc. and Aurigene Discovery Technologies Limited (CURIS INC, Filed With SEC on November 14, 2024)
Second Amended and Restated Research, Collaboration & License Agreement, dated July 31, 2024, by and between the Registrant and the Trustees of the University of Pennsylvania (Passage BIO, Inc., Filed With SEC on November 13, 2024)
Research, Collaboration & License Agreement, dated July 31, 2024, by and between the Registrant and Gemma Biotherapeutics, Inc (Passage BIO, Inc., Filed With SEC on November 13, 2024)
Exclusive License and Collaboration Agreement, effective as of September 9, 2024, with Factor Bioscience Limited (NTN BUZZTIME INC, Filed With SEC on November 12, 2024)
Research Collaboration and License Agreement, dated September 28, 2024, by and between Juno Therapeutics, Inc. and the Registrant (Prime Medicine, Inc., Filed With SEC on November 12, 2024)
Research Collaboration and License Agreement, dated September 13, 2024 between Korro Bio, Inc. and Novo Nordisk A/S (Frequency Therapeutics, Inc., Filed With SEC on November 12, 2024)
Amendment No.4 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated August 28, 2024 (FATE THERAPEUTICS INC, Filed With SEC on November 12, 2024)
Third Amendment to the Collaboration and License Agreement, dated August 14, 2024, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Poseida Therapeutics, Inc., Filed With SEC on November 7, 2024)
Amendments to Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd., dated October 29, 2018 (RIGEL PHARMACEUTICALS INC, Filed With SEC on November 7, 2024)
Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd., dated September 3, 2024 (RIGEL PHARMACEUTICALS INC, Filed With SEC on November 7, 2024)
Fourth Amendment to the Collaboration and License Agreement by and between the Company and Incyte Corporation, Inc., dated July 24, 2024 (MACROGENICS INC, Filed With SEC on November 5, 2024)
Amendment No. 3 entered into as of August 1, 2024 to the Master Collaboration Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (ALNYLAM PHARMACEUTICALS, INC., Filed With SEC on October 31, 2024)
Market Development and Collaboration Agreement (ADiTx Therapeutics, Inc., Filed With SEC on September 23, 2024)
Collaboration and License Agreement by and between Alopexx, Inc and Biotech Consortia, Inc (Alopexx, Inc., Filed With SEC on September 9, 2024)
Clinical Trial Collaboration and Supply Agreement, by and between the Registrant and MSD International GmbH and MSD International Business GmbH, dated May 19, 2022 (Bicara Therapeutics Inc., Filed With SEC on August 22, 2024)
Research and Collaboration Agreement Between Jiangsu Alphamab Biopharmaceuticals Co., Ltd and Arrivent Biopharma, Inc (ArriVent Biopharma, Inc., Filed With SEC on August 14, 2024)
First Amendment to Collaboration and License Agreement, dated as of May 14, 2024, by and between the Registrant and Torii Pharmaceuticals Co., Ltd (Verrica Pharmaceuticals Inc., Filed With SEC on August 14, 2024)
Amendment No. 4 to the Research Collaboration Agreement, dated May 2, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG (Nkarta, Inc., Filed With SEC on August 13, 2024)
Amendment No. 3 to the Research Collaboration Agreement, dated April 3, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG (Nkarta, Inc., Filed With SEC on August 13, 2024)
Amendment No. 1 to Collaboration and License Agreement by and between the Company and Everest Medicines II (HK) Limited, dated as of July 2, 2024 (Kezar Life Sciences, Inc., Filed With SEC on August 13, 2024)
Collaboration and License Agreement dated May 3, 2024 by and among GB002, Inc., Gossamer Bio 002 Ltd. and Gossamer Bio, Inc. on the one hand and CHIESI Farmaceutici S.p.A and... (Gossamer Bio, Inc., Filed With SEC on August 12, 2024)
First Amended and Restated Collaboration Agreement, dated April 2, 2024, by and between Adimab, LLC and Leap Therapeutics, Inc (LEAP THERAPEUTICS, INC., Filed With SEC on August 12, 2024)
Amendment to Research Collaboration and License Agreement with Giiant Pharma, Inc. dated August 2, 2024 (Neuralstem, Inc., Filed With SEC on August 12, 2024)
FNAIT Collaboration Agreement, dated April 9, 2024, by and between Momenta Pharmaceuticals, Inc. and Rallybio IPA, LLC (Rallybio Corp, Filed With SEC on August 8, 2024)
Amendment No. 4 to the Option, License and Collaboration Agreement between Arcus Biosciences, Inc. and Gilead Sciences, Inc., dated May 10, 2024 (Arcus Biosciences, Inc., Filed With SEC on August 8, 2024)
Third Amendment to Collaboration and Commercialization Agreement, by and between the Subsidiary and Ascensia Diabetes Care (Senseonics Holdings, Inc., Filed With SEC on August 8, 2024)
Collaboration Agreement, dated May 6, 2024, between the Registrant and The Swiss Group for Cancer Research SAKK (INTENSITY THERAPEUTICS, INC., Filed With SEC on August 8, 2024)
Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (CytomX Therapeutics, Inc., Filed With SEC on August 8, 2024)
Amendment No. 1 to Amended and Restated Collaboration and License Agreement, dated May 17, 2024, by and between Allogene Therapeutics, Inc. and Notch Therapeutics (Canada) Inc (Allogene Therapeutics, Inc., Filed With SEC on August 7, 2024)
Collaboration Agreement between Rani Therapeutics, LLC and ProGen Co., Ltd. dated June 17, 2024 (Rani Therapeutics Holdings, Inc., Filed With SEC on August 6, 2024)
Addendum to Collaboration and License Agreement between argenx BV and Zai Auto Immune (Hong Kong) Limited dated June 30, 2024 (Zai Lab Ltd, Filed With SEC on August 6, 2024)
First Amendment to Collaboration Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024 (Voyager Therapeutics, Inc., Filed With SEC on August 6, 2024)
Collaboration Agreement, dated as of April 4, 2024, by and between the Company and BiBo Biopharma Engineering Co., Ltd (89bio, Inc., Filed With SEC on August 5, 2024)
Collaboration and License Agreement, by and between the Registrant and Xyphos Biosciences, Inc. dated April 30, 2024 (Poseida Therapeutics, Inc., Filed With SEC on August 5, 2024)
Fifth Amendment to License and Collaboration Agreement between Alkermes Pharma Ireland Limited and Biogen International GmbH (as successor to Biogen Swiss Manufacturing GmbH),... (Alkermes plc., Filed With SEC on July 24, 2024)
Collaboration Agreement (Hypersolar, Inc., Filed With SEC on July 23, 2024)
Collaboration Agreement (Kensington Capital Acquisition Corp., Filed With SEC on July 11, 2024)
Amendment to Collaboration and License Agreement between Innovent Biologics (Suzhou) Co. Ltd. and AnHeart Therapeutics Inc, dated November 30, 2022 (Panacea Acquisition Corp, Filed With SEC on June 20, 2024)